Reply: Platelet reactivity is preferred over genotyping in monitoring efficacy of antiplatelet therapy

JACC Cardiovasc Interv. 2014 Apr;7(4):448-9. doi: 10.1016/j.jcin.2014.01.154.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Coronary Artery Disease / therapy*
  • Drug-Eluting Stents*
  • Female
  • Humans
  • Male
  • Percutaneous Coronary Intervention / instrumentation*
  • Platelet Aggregation / drug effects*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Polymorphism, Genetic*
  • Ticlopidine / analogs & derivatives*

Substances

  • Platelet Aggregation Inhibitors
  • Aryl Hydrocarbon Hydroxylases
  • Ticlopidine